Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
330
datasets available to search
ShareScore release 0.9.0
Dataset results
330 results for “skin cancer”
Mueller matrix imaging combining optical parameters of mice non-melanoma skin cancer tissue
<p>The dataset consists of the Mueller matrix elements and optical parameters acquired from the backscattered light using a CCD camera and Mueller matrix imaging technique.</p><p>This dataset contains 90 samples including 20 feature vectors for SCC, 33 feature vectors for normal and 37 feature vectors for papilloma.</p>
In vitro antiproliferative data of metallodrugs in skin cancer cell lines
<p>Compiled <em>in vitro</em> antitumoral potency (IC<sub>50</sub>, GI<sub>50</sub> and/or TGI values) of metallodrugs in skin cancer cell lines. This information is complemented by structural parameters of each compound testted, such as molecular weight with and without the counter-ion, charge, oxidation state of the metal center and ligand type. Information on the antiproliferative assay is also given, such as type of cell line and incubation time. Additional details are provided when the compounds have been assayed upon light activation (PDT), as part of the NCI-60 panel and if <em>in vivo</em> data is also available.</p>
Test data and analysis script for manuscript: Uncovering the complex relationship between balding, testosterone and skin cancers in men
<p>Test data for the manuscript entitled: "<strong>Uncovering the complex relationship between balding, testosterone and skin cancers in men"</strong><br> <br> Includes: <br> --Readme.txt<br> --folder: example<br> --folder: script</p>
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
ClinicalTrials.gov study NCT04154943. IPD Sharing: YES. Countries: 3. Publications: 2.
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
ClinicalTrials.gov study NCT04913220. IPD Sharing: YES. Countries: 7. Publications: 0.
Acceptance of medical AI in skin cancer screening: A Choice-based Conjoint Survey
<p><strong>Background</strong>: There is a great interest in using artificial intelligence (AI) to screen for skin cancer. This is fueled by a rising incidence of skin cancer and an increasing scarcity of trained dermatologists. AI systems, capable of identifying melanoma, could save lives, enable immediate access to screenings, reduce unnecessary care and healthcare costs. While such AI-based systems are useful from a public health perspective, past research has shown that individual patients are very hesitant about being examined by an AI system. <strong>Objective</strong>: The aim of the present study was twofold. First, to determine how important the attributes provider (in-person physician, physician via teledermatology, AI, vs. personalized AI), costs of screening (free, 10€, 25€, vs. 40€) and waiting time (immediate, 1 day, 1 week, 4 weeks) were for patients’ choices of a particular mode of skin cancer screening. Second, to investigate whether sociodemographic characteristics, especially, age, were systematically related to participants’ individual choices. <strong>Methods</strong>: The study used choice-based conjoint-analysis to examine the acceptance of medical AI for a skin cancer screening from the patient's perspective. Participants responded to twelve choice sets, each containing three screening-variants, where each variant was described through attributes; provider, costs and waiting time. Furthermore, sociodemographic characteristics (age, gender, income, job status, educational background) were assessed. <strong>Results</strong>: 126 (33%) respondents completed the online survey. The results from the conjoint analysis showed that the three attributes were more or less equal important for the participant’s choices, with provider being the most important. Inspecting the individual part worths showed that treatment by a physician was most preferred, followed by e-consultation with a physician and personalized AI. The three AI levels scored significantly lower. Concerning the relationship between sociodemographic characteristics and relative importances we found, that only age showed a significant positive association to the important of the attribute provider (r = 0.21; p < .02). Younger participants put a lesser importance on the provider than older participants. All other correlations were not significant. <strong>Conclusions</strong>: The present study adds to the growing body of research using choice-experiments to investigate the acceptance of artificial intelligence in health contexts. Future studies need to explore the reasons <em>why</em> AI is accepted or rejected and whether sociodemographic characteristics are associated this decision.</p> <p> </p>
Dataset from the Study: "A non-invasive approach to skin cancer diagnosis via graphene electrical tattoos and electrical impedance tomography"
<p>This repository contains the scripts and other resources used in:</p> <p>“A non-invasive approach to skin cancer diagnosis via graphene electrical tattoos and electrical impedance tomography”, Lee H et al. 10.1088/1361-6579/ad3d26</p> <p> </p> <p>>> THIS DATA IS FREE FOR USE IN ANY SCIENTIFIC RESEARCH WITH CITATION (PLEASE USE THE DOI FOR PRECISE CITATION): DOI 10.1088/1361-6579/ad3d26</p> <p> </p> <p>>> IF YOU USE THESE RESOURCES, CITE!!!</p> <p> </p> <p>The repository contains the phantom experimental data and the code and resources to generate the numerical/computational models.</p> <p> </p> <p>Note:</p> <p>Software used in this study:</p> <ul> <li>MATLAB</li> <li>EIDORS </li> </ul> <p>Measurement system used in this study:</p> <ul> <li>Sciospec EIT32 system</li> </ul>
A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.
ClinicalTrials.gov study NCT02650193. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
ClinicalTrials.gov study NCT00899574. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Radiotherapy Related Skin Toxicity: Mepitel® vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer
ClinicalTrials.gov study NCT03047174. IPD Sharing: NO. Countries: 1. Publications: 2.
The Impact of Total Body Skin Examination on Skin Cancer Detection
ClinicalTrials.gov study NCT00765193. IPD Sharing: Not stated. Countries: 1. Publications: 1.
HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer
ClinicalTrials.gov study NCT02165605. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Risk Information and Skin-cancer Education for Undergraduate Prevention
ClinicalTrials.gov study NCT03979872. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
ClinicalTrials.gov study NCT04969419. IPD Sharing: YES. Countries: 1. Publications: 1.
PLANNED VISUAL EDUCATION ABOUT SKIN CANCER
ClinicalTrials.gov study NCT05788939. IPD Sharing: YES. Countries: 1. Publications: 18.
Skin Care for Cancer Patients: A Product Satisfaction Survey
ClinicalTrials.gov study NCT00871429. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
ClinicalTrials.gov study NCT03944941. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Comparison of eBX and Mohs Surgery for Treatment of Early-stage Non-melanoma Skin Cancer a Matched Pair Cohort Study.
ClinicalTrials.gov study NCT03024866. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
ClinicalTrials.gov study NCT00129961. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
ClinicalTrials.gov study NCT00489086. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.